Cooperative group research endeavors in small-cell lung cancer: Current and future directions

Clinical Lung Cancer

Volumn 10, Issue 5, 2009, Pages 322-330

  Sangha, Randeep ^a   Lara Jr , Primo N ^a,b   Adjei, Alex A ^c   Baas, Paul ^d   Choy, Hak ^e   Gaspar, Laurie E ^f   Goss, Glenwood ^g   Saijo, Nagahiro ^h   Schiller, Joan H ^e   Vokes, Everett E ⁱ   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Veterans Administration   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g OTTAWA REGIONAL CANCER CENTRE   (Canada)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clinical trials; Hyperfractionation; Intergroup trials; Limited stage; Platinum resistance; Radiation therapy

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CYCLOPAMINE; CYCLOPHOSPHAMIDE; DAUNORUBICINOL; DOXORUBICIN; DOXORUBICINOL; ETOPOSIDE; GDC 0449; GEMCITABINE; IMC A12; IRINOTECAN; MONOCLONAL ANTIBODY; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NAVELBINE; NOGITECAN; OBLIMERSEN; PACLITAXEL; PLATINUM; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESISTANCE; DRUG SCREENING; ESOPHAGITIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LOADING DRUG DOSE; LUNG SMALL CELL CANCER; NEUTROPENIA; RADIATION DOSE; REVIEW;

EID: 77249165606     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.044     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Davies AM, Evans WK, Mackay JA, et al. Treatment of recurrent small cell lung cancer. Hematol Oncol Clin North Am 2004; 18:387-416.
3. Wakelee H, Langer C, Vokes E, et al. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer 2008; 9:9-15. (Pubitemid 351251595)
4. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. J Clin Oncol 2002; 20:4665-4672
5. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618-1624
6. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890-895
7. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11:336-344
8. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage smallcell lung cancer. J Clin Oncol 2004; 22:4837-4845
9. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-271
10. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341:476-484
11. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357:664-672
12. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 2000; 18:1351-1359
13. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007; 12:1096-1104
14. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912-918
15. Choi NC, Herndon JE II, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionatedaccelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998; 16:3528-3536
16. Bogart JA, Herndon JE II, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004; 59:460-468
17. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 2005; 62:342-350
18. Gandara DR, Lara PN Jr, Natale R, et al. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol 2008; 26:4236-4238
19. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:2114-2122
20. Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colonystimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005; 23:3752-3759
21. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23:6854-6864
22. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007; 25:3945-3951
23. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensivestage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26:870-876
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-255 (Pubitemid 44917502)
25. Dowell J, Amirkhan RH, Lai WS, et al. Survival in small cell lung cancer (SCLC) is independent of vascular endothelial growth factor (VEGF) and cyclooxygenase2 (COX-2) expression. Proc Am Soc Clin Oncol 2003; 22: (Abstract 2451).
26. Sandler A, Szwaric S, Dowlati A, et al. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25(18 suppl):400s (Abstract 7564).
27. Ready N, Dudek AZ, Wang XF, et al. CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol 2007; 25(18 suppl):400s (Abstract 7563).
28. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422:313-317
29. Subramanian J, Govindan R. Small cell, big problem! Stem cells, root cause? Clin Lung Cancer 2008; 9:252-253
30. LoRusso PM, Rudin CM, Borad MJ, et al. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. J Clin Oncol 2008; 26(15 suppl):157s (Abstract 3516).
31. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83:355-367
32. Tsurutani J, West KA, Sayyah J, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005; 65:8423-8432
33. Suzuki T, Minamide S, Iwasaki T, et al. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 1997; 15:219-225
34. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006; 24:5448-5453
35. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008; 26:5401-5406
36. Le Péchoux C, Hatton M, Kobierska A, et al. Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): primary endpoint analysis (PCI99-01, IFCT 99-01, EORTC 22003-108004, RTOG 0212). J Clin Oncol 2008; 26(15 suppl):400s (Abstract LBA7514).
37. Komaki R, Moughan J, Ettinger D, et al. Toxicities in a phase II study of accelerated high dose thoracic radiation therapy (TRT) with concurrent chemotherapy for limited small cell lung cancer (LSCLC) (RTOG 0239). J Clin Oncol 2007; 25(18 suppl):438s (Abstract 7717).
38. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S024.
39. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91.
40. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24:2038-2043
41. Gitlitz BJ, Glisson BS, Moon J, et al. Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): A SWOG (S0435) phase II trial. J Clin Oncol 26(15 suppl):433s (Abstract 8039).